AAAAAA

   
Results: 1-22 |
Results: 22
Growth inhibitory effects and radiosensitization induced by fatty aromaticacids on human cervical cancer cells
Authors: Ferrandina, G Filippini, P Ferlini, C Maggiano, N Stoler, AB Fruscella, E Mozzetti, S Mancuso, S Freedman, RS Scambia, G Ranelletti, FO
Citation: G. Ferrandina et al., Growth inhibitory effects and radiosensitization induced by fatty aromaticacids on human cervical cancer cells, ONCOL RES, 12(9-10), 2001, pp. 429-440
Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report
Authors: Azevedo, P Verschraegen, CF Kavanagh, JJ Kudelka, AP Freedman, RS Lu, K Deavers, MT
Citation: P. Azevedo et al., Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report, EUR J GYN O, 22(5), 2001, pp. 319-321
Maturation of dendritic cells from ovarian cancer patients
Authors: Zavadova, E Savary, CA Templin, S Verschraegen, CF Freedman, RS
Citation: E. Zavadova et al., Maturation of dendritic cells from ovarian cancer patients, CANC CHEMOT, 48(4), 2001, pp. 289-296
Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma
Authors: Hosing, C Freedman, RS McLaughlin, P Malpica, A Fornage, BD Kudelka, AP
Citation: C. Hosing et al., Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma, AM J CL ONC, 24(2), 2001, pp. 204-208
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of advanced ovarian cancer
Authors: Donato, ML Gershenson, DM Wharton, JT Ippoliti, CM Aleman, AS Bodurka-Bevers, D Bevers, MW Burke, TW Levenback, CF Wolf, JK Freedman, RS Bast, RC Gajewski, JL Champlin, RE
Citation: Ml. Donato et al., High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of advanced ovarian cancer, GYNECOL ONC, 82(3), 2001, pp. 420-426
Gynecologic problems in patients with breast cancer
Authors: Ramirez, PT Freedman, RS
Citation: Pt. Ramirez et Rs. Freedman, Gynecologic problems in patients with breast cancer, MDA CANC CA, 2001, pp. 382-405
Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis
Authors: Borchardt, PE Quadri, SM Freedman, RS Vriesendorp, HM
Citation: Pe. Borchardt et al., Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis, CANC BIO R, 15(1), 2000, pp. 53-64
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma
Authors: Freedman, RS Kudelka, AP Kavanagh, JJ Verschraegen, C Edwards, CL Nash, M Levy, L Atkinson, EN Zhang, HZ Melichar, B Patenia, R Templin, S Scott, W Platsoucas, CD
Citation: Rs. Freedman et al., Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma, CLIN CANC R, 6(6), 2000, pp. 2268-2278
Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancercell lines
Authors: Hu, W Wu, WG Nash, MA Freedman, RS Kavanagh, JJ Verschraegen, CF
Citation: W. Hu et al., Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancercell lines, ANTICANC R, 20(2A), 2000, pp. 729-733
Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3(+) tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis
Authors: Melichar, B Nash, MA Lenzi, R Platsoucas, CD Freedman, RS
Citation: B. Melichar et al., Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3(+) tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis, CLIN EXP IM, 119(1), 2000, pp. 19-27
Molecular abundances in the atmosphere of the T dwarf G1 229B
Authors: Saumon, D Geballe, TR Leggett, SK Marley, MS Freedman, RS Lodders, K Fegley, B Sengupta, SK
Citation: D. Saumon et al., Molecular abundances in the atmosphere of the T dwarf G1 229B, ASTROPHYS J, 541(1), 2000, pp. 374-389
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer
Authors: Vadhan-Raj, S Verschraegen, CF Bueso-Ramos, C Broxmeyer, HE Kudelka, AP Freedman, RS Edwards, CL Gershenson, D Jones, D Ashby, M Kavanagh, JJ
Citation: S. Vadhan-raj et al., Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer, ANN INT MED, 132(5), 2000, pp. 364-368
The role of cytokines in both the normal and malignant ovary
Authors: Nash, MA Ferrandina, G Gordinier, M Loercher, A Freedman, RS
Citation: Ma. Nash et al., The role of cytokines in both the normal and malignant ovary, ENDOCR-R CA, 6(1), 1999, pp. 93-107
Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma
Authors: Gordinier, ME Zhang, HZ Patenia, R Levy, LB Atkinson, EN Nash, MA Katz, RL Platsoucas, CD Freedman, RS
Citation: Me. Gordinier et al., Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma, CLIN CANC R, 5(9), 1999, pp. 2498-2505
Long-term results and pharmacokinetics of high-dose paclitaxel in patientswith refractory epithelial ovarian carcinoma
Authors: Kudelka, AP Verschraegen, CF Shen, Y De Leon, CG Edwards, CL Freedman, RS Forman, A Gibbs, HR Mante, R Hord, M Canetta, R Krakoff, I Kavanagh, JJ
Citation: Ap. Kudelka et al., Long-term results and pharmacokinetics of high-dose paclitaxel in patientswith refractory epithelial ovarian carcinoma, INT J GYN C, 9(1), 1999, pp. 44-53
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
Authors: Verschraegen, CF Gupta, F Loyer, E Kavanagh, JJ Kudelka, AP Freedman, RS Edwards, CL Harris, N Steger, M Steltz, V Giovanella, BC Stehlin, JS
Citation: Cf. Verschraegen et al., A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer, ANTI-CANC D, 10(4), 1999, pp. 375-383
The role of macrophages in antitumor defense of patients with ovarian cancer
Authors: Zavadova, E Loercher, A Verstovsek, S Verschraegen, CE Micksche, M Freedman, RS
Citation: E. Zavadova et al., The role of macrophages in antitumor defense of patients with ovarian cancer, HEMAT ONCOL, 13(1), 1999, pp. 135
Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells
Authors: Loercher, AE Nash, MA Kavanagh, JJ Platsoucas, CD Freedman, RS
Citation: Ae. Loercher et al., Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells, J IMMUNOL, 163(11), 1999, pp. 6251-6260
In vitro growth inhibition of ovarian cancer cells by decorin: Synergism of action between decorin and carboplatin
Authors: Nash, MA Loercher, AE Freedman, RS
Citation: Ma. Nash et al., In vitro growth inhibition of ovarian cancer cells by decorin: Synergism of action between decorin and carboplatin, CANCER RES, 59(24), 1999, pp. 6192-6196
Galileo probe measurements of thermal and solar radiation fluxes in the Jovian atmosphere
Authors: Sromovsky, LA Collard, AD Fry, PM Orton, GS Lemmon, MT Tomasko, MG Freedman, RS
Citation: La. Sromovsky et al., Galileo probe measurements of thermal and solar radiation fluxes in the Jovian atmosphere, J GEO R-PLA, 103(E10), 1998, pp. 22929-22977
Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines
Authors: Melichar, B Ferrandina, G Verschraegen, CF Loercher, A Abbruzzese, JL Freedman, RS
Citation: B. Melichar et al., Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines, CLIN CANC R, 4(12), 1998, pp. 3069-3076
A phase II trial of high-dose hydroxyurea administered parenterally in patients with epithelial ovarian carcinoma refractory to platinum
Authors: Verschraegen, CF Kudelka, AP Loyer, E Edwards, CL Freedman, RS Kavanagh, JJ
Citation: Cf. Verschraegen et al., A phase II trial of high-dose hydroxyurea administered parenterally in patients with epithelial ovarian carcinoma refractory to platinum, INT J GYN C, 8(6), 1998, pp. 494-498
Risultati: 1-22 |